Article Text

Extended report
Smokers in early axial spondyloarthritis have earlier disease onset, more disease activity, inflammation and damage, and poorer function and health-related quality of life: results from the DESIR cohort
  1. Ho Yin Chung1,2,
  2. Pedro Machado1,3,
  3. Désirée van der Heijde1,
  4. Maria-Antonietta D'Agostino4,
  5. Maxime Dougados5
  1. 1Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands
  2. 2Department of Rheumatology and Clinical Immunology, University of Hong Kong, Hong Kong, China
  3. 3Department of Rheumatology, Coimbra University Hospital, Coimbra, Portugal
  4. 4Department of Rheumatology, Ambroise Paré Hospital, Boulogne-Billancourt, France
  5. 5Rheumatology B Department, APHP, Cochin Hospital, Paris-Descartes University, Paris, France
  1. Correspondence to Professor Maxime Dougados, Rheumatology B Department, Cochin Hospital, Paris 75014, France; m.doug{at}cch.aphp.fr

Footnotes

  • Funding The DESIR study is conducted as a Programme Hospitalier de Recherche Clinique (PHRC) with Assistance Publique–Hôpitaux de Paris as the sponsor. The DESIR study is also under the umbrella of the French Society of Rheumatology, which is also financially supporting the cohort. An unrestricted grant from Pfizer has been allocated for the first 5 years. PM was supported by the Fundação para a Ciência e a Tecnologia (FCT) grant SFRH/BD/62329/2009.

  • Competing interests None.

  • Patient consent Obtained.

  • Ethics approval The DESIR study was approved by the French Departmental Directorate of Health and Social Affairs (Directeur Départemental des Affaires Sanitaires et Sociales) and has obtained the approval of the appropriate local ethics committees. It was conducted in accordance with the Declaration of Helsinki and the guidance for good clinical practice (French version), 30 November 2006.

  • Provenance and peer review Not commissioned; externally peer reviewed.

View Full Text

Statistics from Altmetric.com

Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement:

    • Web Only Data - This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
    • Web Only Data - This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Footnotes

  • Funding The DESIR study is conducted as a Programme Hospitalier de Recherche Clinique (PHRC) with Assistance Publique–Hôpitaux de Paris as the sponsor. The DESIR study is also under the umbrella of the French Society of Rheumatology, which is also financially supporting the cohort. An unrestricted grant from Pfizer has been allocated for the first 5 years. PM was supported by the Fundação para a Ciência e a Tecnologia (FCT) grant SFRH/BD/62329/2009.

  • Competing interests None.

  • Patient consent Obtained.

  • Ethics approval The DESIR study was approved by the French Departmental Directorate of Health and Social Affairs (Directeur Départemental des Affaires Sanitaires et Sociales) and has obtained the approval of the appropriate local ethics committees. It was conducted in accordance with the Declaration of Helsinki and the guidance for good clinical practice (French version), 30 November 2006.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.